The journey of canakinumab; on- and off-label indications
Beyond Rheumatology · 2019
DOI: 10.4081/br.2019.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Beyond Rheumatology, 2019. Verfasst von Daniela Marotto und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarise the on- and off-label use of canakinumab (ILARIS®).
Zitieren
APA
Marotto, D., Batticciotto, A., Ceribelli, A., & Puttini, P. S. (2019). The journey of canakinumab; on- and off-label indications. Beyond Rheumatology. https://doi.org/10.4081/br.2019.4
Vancouver
Marotto D, Batticciotto A, Ceribelli A, Puttini PS. The journey of canakinumab; on- and off-label indications. Beyond Rheumatology. 2019. doi:10.4081/br.2019.4
BibTeX
@article{Marotto2019,
author = {Marotto, Daniela and Batticciotto, Alberto and Ceribelli, Angela and Puttini, Piercarlo Sarzi},
title = {The journey of canakinumab; on- and off-label indications},
journal = {Beyond Rheumatology},
year = {2019},
doi = {10.4081/br.2019.4}
}
EUVIMED